Moleculin Biotech, Inc. Net Fee Amt
Moleculin Biotech, Inc. (MBRX) had Net Fee Amt of $5.52 thousand as of 2026-07-29, per its S-1 filed 2026-07-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-29
- 2026-07-29: Net Fee Amt $5.52K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-29 | $5.52K S-1 · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |